Treatment of drug‐eluting stent restenosis with the same versus different drug‐eluting stent

The authors aimed to compare the clinical outcomes with repeat drug‐eluting stent (DES) implantation utilizing the same type versus an alternate DES type for in‐stent restenosis (ISR) of DES.

[1]  K. Kent,et al.  Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. , 2006, The American journal of cardiology.

[2]  Raghava R. Gollapudi,et al.  Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. , 2006, The American journal of cardiology.

[3]  E. Edelman,et al.  Pushing drug-eluting stents into uncharted territory: simpler than you think--more complex than you imagine. , 2006, Circulation.

[4]  G. Stone,et al.  Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.

[5]  P. Teirstein,et al.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.

[6]  J. Popma,et al.  Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice , 2005, Circulation.

[7]  P. Giannakakou,et al.  Resistance to Microtubule-Stabilizing Drugs Involves Two Eventse: β-Tubulin Mutation in One Allele Followed by Loss of the Second Allele , 2005, Cell cycle.

[8]  F. Fernández‐Avilés,et al.  Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.

[9]  Gregg W Stone,et al.  Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.

[10]  A. Kastrati,et al.  Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.

[11]  P. Teirstein,et al.  Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. , 2005, The Journal of invasive cardiology.

[12]  G. Stone,et al.  Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. , 2005, The American journal of cardiology.

[13]  A. Kastrati,et al.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.

[14]  E. Bramucci,et al.  Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. , 2004, JAMA.

[15]  R. Virmani,et al.  Preclinical restenosis models and drug-eluting stents: still important, still much to learn. , 2004, Journal of the American College of Cardiology.

[16]  R. Virmani,et al.  Drug-eluting stents: caution and concerns for long-term outcome , 2004, Coronary artery disease.

[17]  P. Serruys,et al.  Post–Sirolimus-Eluting Stent Restenosis Treated With Repeat Percutaneous Intervention: Late Angiographic and Clinical Outcomes , 2004, Circulation.

[18]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[19]  Patrick W Serruys,et al.  Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry , 2004, Circulation.

[20]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[21]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[22]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[23]  Shile Huang,et al.  Rapamycins: Mechanisms of Action and Cellular Resistance , 2003, Cancer biology & therapy.

[24]  Antonio Colombo,et al.  Selection of coronary stents. , 2002, Journal of the American College of Cardiology.

[25]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[26]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[27]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[28]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[29]  E. Perin.  Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS. , 2005, Reviews in cardiovascular medicine.

[30]  A. Gershlick,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS) , 2004 .

[31]  鈴木 健.  Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model , 2003 .

[32]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.

[33]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[34]  B R Goldspiel,et al.  Paclitaxel (Taxol) , 1994, Pharmacotherapy.